Research graph
References from PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; tovorafenib and dordaviprone for glioma, mirvetuximab soravtansine and pembrolizumab for ovarian cancer, tislelizumab for nasopharyngeal cancer, trastuzumab deruxtecan, palbociclib and datopotamab deruxtecan for breast cancer, epcoritamab for lymphoma, teclistamab for multiple myeloma. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
External reference
10.1038/s41591-023-02668-y
10.1038/s41591-023-02668-y · 2024 · External reference
10.1056/nejmoa2309169
10.1056/nejmoa2309169 · 2023 · External reference
10.1200/jco.23.01134
10.1200/jco.23.01134 · 2024 · External reference
10.1016/j.ccell.2023.04.014
10.1016/j.ccell.2023.04.014 · 2023 · External reference
10.1056/nejmoa2508668
10.1056/nejmoa2508668 · 2026 · External reference
10.1016/s0140-6736(26)00602-1
10.1016/s0140-6736(26)00602-1 · 2026 · External reference
10.1016/s0140-6736(25)02360-8
10.1016/s0140-6736(25)02360-8 · 2026 · External reference
10.1056/nejmoa2511218
10.1056/nejmoa2511218 · 2026 · External reference
10.1056/nejmoa2514663
10.1056/nejmoa2514663 · 2026 · External reference
10.1016/j.annonc.2026.03.008
10.1016/j.annonc.2026.03.008 · 2026 · External reference
Unresolved reference
External reference
